Gender differences in Parkinson's disease
Gender differences in Parkinson's disease
复制标题
DOI：
10.1016/s1550-8579(07)80003-9
复制
发表时间：
2007-03-01
期刊：
影响因子：
--
通讯作者：
Shulman, Lisa M.
中科院分区：
文献类型：
--
作者：
Shulman, Lisa M.
由于雌激素对多巴胺神经传递有多种影响，许多研究人员对其可能用于减缓帕金森病（PD）的进展或降低其风险感兴趣。男性帕金森病的发病率高于女性。神经毒性的性别差异已经被观察到，实验动物的基础研究表明，雌激素可以保护神经元免受各种形式的损伤。然而，关于雌激素替代对PD的神经保护作用的回顾性调查结果好坏参半，有些显示对风险没有影响，有些显示风险降低。在残疾和生活质量报告方面存在轻微的显著的性别差异，妇女认为残疾更严重，生活质量下降。性别差异已经在PD治疗的反应中显示出来，例如，左旋多巴的代谢方式——女性左旋多巴的生物利用度更高。在绝经期帕金森病雌激素替代治疗（POETRY）研究中，参与者发现在统一帕金森病评定量表上得分有所提高。基于poem的结果，我们假设雌激素替代疗法（ERT）可能导致PD症状的改善，并为减少女性抗帕金森药物的剂量提供了机会。
Because estrogen has numerous effects on dopamine neurotransmission, many researchers are interested in its possible use to either slow the progression or reduce the risk of Parkinson's disease (PD). The incidence of PD is greater in men than in women. Gender differences in neurotoxicity have been observed, and basic research in experimental animals indicates that estrogen protects neurons from various forms of injury. However, the results of retrospective surveys of the neuroprotective effects of estrogen replacement in PD have been mixed, with some showing no effect on risk and others showing a reduction in risk. A mildly significant gender difference in disability and quality-of-life reporting has been noted, with women citing greater disability and reduced quality of life. Gender differences have been shown in response to treatment of PD, for example, in how levodopa is metabolized-women have greater levodopa bioavailability. In the Parkinson's Disease on Estrogen Therapy Replacement in the Menopause Years (POETRY) study, participants were found to have improved scores on the Unified Parkinson Disease Rating Scale. Based on the POETRY results, it is hypothesized that estrogen replacement therapy (ERT) may lead to improvement in PD symptoms and provide an opportunity to reduce the dosage of antiparkinsonian medication in women.